View Cart  

Pfizer, Medivation Terminate Dimebon Development After Failed Alzheimer’s Trial

A A
Pfizer and Medivation are discontinuing their co-development of Dimebon in all indications after another late-stage Alzheimer’s trial missed its primary endpoints.

To View This Article:

Login

Subscribe To Drug Industry Daily